Data From Adherex's European Phase Ib/II Trial of ADH-1 to be,Presented at International Symposium on Targeted Anticancer,Therapies ( rapidly progressive (eight and sixmon...)

HOME >> MEDICINE >> TECHNOLOGY

Data From Adherex's European Phase Ib/II Trial of ADH-1 to be,Presented at International Symposium on Targeted Anticancer,Therapies

rapidly progressive (eight and six months, respectively). Two other patients experienced stabilization of their disease, one with colorectal cancer and one with non-small cell lung cancer, each lasting three months.

Adherex is currently evaluating the synergy of ADH-1 in combination with chemotherapy in a Phase I trial of ADH-1 in three separate combinations: ADH-1 + docetaxel (Taxotere(R)), ADH-1 + carboplatin, and ADH-1 + capecitabine (Xeloda(R)). A Phase I study of ADH-1 in combination with melphalan for the treatment of melanoma is expected to initiate in the coming weeks. In addition to the European Phase Ib/II study of single-agent ADH-1 to be presented today, the Company has also completed patient enrollment in a North American Phase II study of single-agent ADH-1 and data from that trial is expected to be presented at an appropriate scientific venue in 2007.

About Adherex Technologies

Adherex Technologies Inc. is a biopharmaceutical company dedicated to the discovery and development of novel cancer therapeutics. We aim to be a leader in developing innovative treatments that address important unmet medical needs in cancer. We currently have multiple products in the clinical stage of development, including eniluracil, ADH-1 and sodium thiosulfate (STS). Eniluracil, an oral dihydropyrimidine dehydrogenase (DPD) inhibitor, was previously under development by GlaxoSmithKline for oncology indications. ADH-1, our lead biotechnology compound, selectively targets N-cadherin, a protein present on certain tumor cells and established blood vessels that feed solid tumors. STS, a drug from our specialty pharmaceuticals pipeline, protects against the disabling hearing loss that can often result from treatment with platinum-based chemotherapy drugs. With a diversified portfolio of unique preclinical and clinical-stage cancer compounds and a management team with expertise in identifying, developing and commercializing novel cancer therapeutics, Adherex
'"/>

Page: 1 2 3
Related medicine technology :

1. Generex Biotechnology to Make Presentations At 46th Annual Meeting of the European Society of Pediatric Endocrinology
2. Positive ZIO-201 Interim Phase II Sarcoma Data Presented at European Society for Medical Oncology
3. DOR BioPharma Announces Issuance of European Patent for Its Oral Multivalent Botulinum Toxin Vaccine BT-VACC
4. European Society for Medical Oncology (ESMO) Presents Data from the Clinical Trial of MediGenes Cancer-Killing Virus in Press Conference
5. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
6. Malvern initiates European user group meetings for chemical imaging
7. PARI Pharma Presents Study Results of Sinus Delivery and Inhaled Liposomal Ciclosporin A at European Cystic Fibrosis Conference
8. Targeted Genetics Reports Inflammatory Arthritis Clinical Data at European Rheumatology Conference
9. Can-Fite Proceeds with Development of Third Drug; Progress in Development of CF502 Will Be Presented at the Annual European Congress of Rheumatology
10. Inspire Announces Presentations at Two European Scientific Conferences
11. Sunesis Pharmaceuticals Reports Positive Data From Studies of Two Anti-Cancer Agents, SNS-595 and SNS-032, at the 12th Congress of the European Hematology Association

Post Your Comments:

(Date:12/2/2009)...ORK, Dec. 2 Interleukin ...Medical Center announced findings from a study per...e genetics of osteoarthritis have been published t...ls of Rheumatic Diseases and is available at http.... Results from the study highlight importance ...

(Date:12/2/2009)... Decision Resources, one of the wor...aceutical and healthcare issues, finds that generi...antipsychotics will cause the schizophrenia drug m...2 billion in 2013 in the United States, France, Ge... ,, The new Pharmacor report entitled Schizoph...

(Date:12/2/2009)...swire-FirstCall/ -- Keryx Biopharmaceuticals, Inc....od and Drug Administration (FDA) has granted Fast ...ompany,s novel, potentially first-in-class, oral a...e 3-kinase (PI3K)/Akt pathway, for the treatment o...e Fast Track program of the FDA is designed to fac...

Breaking Medicine Technology:Interleukin Genetics and NYU Langone Medical Center Announce Publication of Study on Genetics of Osteoarthritis 2 Interleukin Genetics and NYU Langone Medical Center Announce Publication of Study on Genetics of Osteoarthritis 3 Interleukin Genetics and NYU Langone Medical Center Announce Publication of Study on Genetics of Osteoarthritis 4 Generic Erosion of Established Branded Atypical Antipsychotics Will Cause the Schizophrenia Drug Market To Decline More Than $1 Billion by 2013 2 Keryx Receives FDA Fast Track Designation for KRX-0401 (Perifosine) for the Treatment of Relapsed/Refractory Multiple Myeloma 2 Keryx Receives FDA Fast Track Designation for KRX-0401 (Perifosine) for the Treatment of Relapsed/Refractory Multiple Myeloma 3 Keryx Receives FDA Fast Track Designation for KRX-0401 (Perifosine) for the Treatment of Relapsed/Refractory Multiple Myeloma 4 Victhom announces completion of joint venture agreement with Otto Bock for Neurobionix activities 12700 1 Victhom announces completion of joint venture agreement with Otto Bock for Neurobionix activities 12700 2 Victhom announces completion of joint venture agreement with Otto Bock for Neurobionix activities 12700 3 Victhom announces completion of joint venture agreement with Otto Bock for Neurobionix activities 12700 4 Long term care costs exceed yearly income for many Calif seniors living alone 49402 1 Long term care costs exceed yearly income for many Calif seniors living alone 49402 2 Long term care costs exceed yearly income for many Calif seniors living alone 49402 3 JourneyLite of Houston Receives Center of Excellence Accreditation 49400 1 JourneyLite of Houston Receives Center of Excellence Accreditation 49400 2 JourneyLite of Houston Receives Center of Excellence Accreditation 49400 3

[0] Interleukin Genetics and NYU Langone Medical Center Announce Publication of Study on Genetics of Osteoarthritis [0] Generic Erosion of Established Branded Atypical Antipsychotics Will Cause the Schizophrenia Drug Market To Decline More Than $1 Billion by 2013 [0] Keryx Receives FDA Fast Track Designation for KRX-0401 (Perifosine) for the Treatment of Relapsed/Refractory Multiple Myeloma

...ion of a Small Molecule with Dem...., May 16 Nektar,Therapeutics (Nasdaq: NKTR ) an... of NKTR- 102, PEGylated irinotecan. The data show... refractory solid tumors. The study,also demonstra...logy,produced an increase in SN38 exposure that wa...

...n Most Affected by Disease -, WAYNE, N.J. and EME...uticals, Inc. and Onyx Pharmaceuticals, Inc.,(Nasd...enib) tablets,significantly improved overall survi...tients in the Asia-Pacific region with advanced,he...cer versus those,receiving placebo. Nexavar also s...

Other Medicine Technology:Significant Anti-Tumor Activity of NKTR-102 in Patients With Refractory Solid Tumors; Interim Data Published in ASCO 2008 Proceedings 2 Significant Anti-Tumor Activity of NKTR-102 in Patients With Refractory Solid Tumors; Interim Data Published in ASCO 2008 Proceedings 3 Significant Anti-Tumor Activity of NKTR-102 in Patients With Refractory Solid Tumors; Interim Data Published in ASCO 2008 Proceedings 4 Significant Anti-Tumor Activity of NKTR-102 in Patients With Refractory Solid Tumors; Interim Data Published in ASCO 2008 Proceedings 5 Nexavar Significantly Improves Overall Survival by 47 Percent in Asia-Pacific Liver Cancer Study 2 Nexavar Significantly Improves Overall Survival by 47 Percent in Asia-Pacific Liver Cancer Study 3 Nexavar Significantly Improves Overall Survival by 47 Percent in Asia-Pacific Liver Cancer Study 4 Nexavar Significantly Improves Overall Survival by 47 Percent in Asia-Pacific Liver Cancer Study 5 Nexavar Significantly Improves Overall Survival by 47 Percent in Asia-Pacific Liver Cancer Study 6

Significant Anti-Tumor Activity of NKTR-102 in Patients With Refractory Solid Tumors; Interim Data Published in ASCO 2008 Proceedings Nexavar Significantly Improves Overall Survival by 47 Percent in Asia-Pacific Liver Cancer Study

(Date:12/2/2009)...ifornia Institute of Technology (Caltech) have bee...the previously mysterious process by which long ch...zymes called ubiquitin ligases to proteins that co...proteins for destruction by protein-degrading comp...gases build ubiquitin chains very rapidly by trans...

(Date:12/2/2009)...the European Association of Echocardiography (EAE)...ardiology, where techniques of non-invasive diagno...rts will be presented at this year,s Congress, wit...s new technology. , Now, with such rapid develo...-invasive imaging will gain more importance in cli...

(Date:12/2/2009)...een a top name in the medical supply industry sinc...rofessional staff, and a keen understanding of the...ablished itself as a provider of ground ambulance ...pplies distributor. The distinguished history of t...t phase with the redesign and launch of its websit...

(Date:12/2/2009)...an 900 runners and walkers from Las Vegas and arou...ock ‘n’ Roll Las Vegas Half Marathon p...r the Crohn,s & Colitis Foundation through its...ww.ccteamchallenge). As the official charity of th...on, and support initiatives to benefit the 1.4 mil...

(Date:12/2/2009)... In response to rising suicide and divorce rates w...ministry dedicated to supporting marriages and fam... marriage conference at a significant discount to...the Grand Hyatt Atlanta in Buckhead (3300 Peachtre...etaway aimed at strengthening healthy marriages an...

Breaking Medicine News(10 mins):Health News:Caltech scientists show how ubiquitin chains are added to cell-cycle proteins 2 Health News:Caltech scientists show how ubiquitin chains are added to cell-cycle proteins 3 Health News:Caltech scientists show how ubiquitin chains are added to cell-cycle proteins 4 Health News:Media alert: EUROECHO 2009 2 Health News:From A to B and Everything In-between; AB First Aid Launch New Web Storefront 2 Health News:From A to B and Everything In-between; AB First Aid Launch New Web Storefront 3 Health News:Raising Millions for Team Challenge through Rock ‘n' Roll Las Vegas Half Marathon Program Brings Hundreds From Across the Country to Raise Funds for Crohn's & Colitis 2 Health News:Raising Millions for Team Challenge through Rock ‘n' Roll Las Vegas Half Marathon Program Brings Hundreds From Across the Country to Raise Funds for Crohn's & Colitis 3 Health News:Raising Millions for Team Challenge through Rock ‘n' Roll Las Vegas Half Marathon Program Brings Hundreds From Across the Country to Raise Funds for Crohn's & Colitis 4 Health News:FamilyLife Supports Military Marriages in Atlanta 2

[1] Caltech scientists show how ubiquitin chains are added to cell-cycle proteins [0] Media alert: EUROECHO 2009 [0] From A to B and Everything In-between; AB First Aid Launch New Web Storefront [0] Raising Millions for Team Challenge through Rock ‘n' Roll Las Vegas Half Marathon Program Brings Hundreds From Across the Country to Raise Funds for Crohn's & Colitis [0] FamilyLife Supports Military Marriages in Atlanta

...ed From Hospital Within 24-48 Hours, TYLER, Texas...st brain tumor patient in the region to benefit fr...ary tumors without making incisions,in the skin. S...rgeon in the region to offer patients an endoscopi...

...., Oct. 18 Omnicell, Inc.,(Nasdaq: OMCL ), a lea...are,facilities, today announced results for its th...s: Revenues for the third quarter of 2007 totaled .... Third quarter 2007 net income as reported in ac...

.... 18 Pennsylvania AFL-CIO,President William George...ennsylvania,s U.S. House Delegation who voted in f...76, the Children,s Health Insurance Program,Act of...st providing health insurance for the growing numb...

...C. -- A research team from the Northern California...nia, and Wake Forest University School of Medicine...ich increases levels of vitamin D in the body ,-- ...d that women with high sun exposure had half the r...

...ial seeks to predict who is most likely to experie...ental treatment can prevent it altogether. Physici... a knee injury, seeking to understand why nearly h...h year. , The work is funded by a special class ...

... Following is a statement from Greg,Tarpinian, Exe...ailure to,override President Bush,s veto of SCHIP....essional Democrats and,some courageous Republicans...CHIP, President Bush and his Republican allies,in ...

Video: Trinity Mother Frances Neurosurgeon First in Region to Remove Brain Tumor Using Unique Surgical Procedure Omnicell Reports Strong Q3 Revenue and Profit Growth Shameful Votes Today on Children's Health Care by Reps. John Peterson, Joe Pitts and Bill Shuster Exposure to sunlight may decrease risk of advanced breast cancer by half What's been causing your knee to ache? Smurfs!273 Lawmakers Put Kids First

Fluoronav Virtual Fluoroscopy System

Fluoro-Spine with Fluorotrak 3500

ZEPHIR Anterior Cervical Plate System

... premium 16-slice CT scanner. From streamlining t...y delivering high quality, advanced results, the M...tform that has been the most popular in the indust...ent literally within seconds, and with a high degr...

Medicine Products:

Fluoronav Virtual Fluoroscopy System Fluoro-Spine with Fluorotrak 3500 ZEPHIR Anterior Cervical Plate System Mx8000 IDT 16 Multislice CT

( rapidly progressive (eight and sixmon...)Data From Adherex's European Phase Ib/II Trial of ADH-1 to be,Presented at International Symposium on Targeted Anticancer,Therapies,Health